Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/20628086http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/20628086http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/20628086http://www.w3.org/2000/01/rdf-schema#comment"

Objective

Thiazolidinediones are used to treat type 2 diabetes. Their use has been associated with peripheral edema and congestive heart failure-outcomes that may have a genetic etiology.

Research design and methods

We genotyped 4,197 participants of the multiethnic DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial with a 50k single nucleotide polymorphisms (SNP) array, which captures ∼2000 cardiovascular, inflammatory, and metabolic genes. We tested 32,088 SNPs for an association with edema among Europeans who received rosiglitazone (n = 965).

Results

One SNP, rs6123045, in NFATC2 was significantly associated with edema (odds ratio 1.89 [95% CI 1.47-2.42]; P = 5.32 × 10(-7), corrected P = 0.017). Homozygous individuals had the highest edema rate (hazard ratio 2.89, P = 4.22 × 10(-4)) when compared with individuals homozygous for the protective allele, with heterozygous individuals having an intermediate risk. The interaction between the SNP and rosiglitazone for edema was significant (P = 7.68 × 10(-3)). Six SNPs in NFATC2 were significant in both Europeans and Latin Americans (P < 0.05).

Conclusions

Genetic variation at the NFATC2 locus contributes to edema among individuals who receive rosiglitazone."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.org/dc/terms/identifier"doi:10.2337/dc10-0452"xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Anand S."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Anand S."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Xie C."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Xie C."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Diaz R."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Diaz R."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Do R."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Do R."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Engert J.C."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Engert J.C."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Montpetit A."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Montpetit A."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Keavney B."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Keavney B."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Mohan V."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Mohan V."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Bailey S.D."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Bailey S.D."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Gerstein H.C."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Gerstein H.C."xsd:string
http://purl.uniprot.org/citations/20628086http://purl.uniprot.org/core/author"Yusuf S."xsd:string
▶